Los Angeles Capital Management LLC Has $1.17 Million Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Los Angeles Capital Management LLC grew its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 55.8% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 76,616 shares of the biopharmaceutical company’s stock after buying an additional 27,437 shares during the period. Los Angeles Capital Management LLC’s holdings in TG Therapeutics were worth $1,165,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Pingora Partners LLC acquired a new position in shares of TG Therapeutics during the fourth quarter valued at about $27,000. PNC Financial Services Group Inc. raised its position in shares of TG Therapeutics by 131.7% during the third quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,014 shares during the last quarter. Anchor Investment Management LLC acquired a new position in shares of TG Therapeutics during the fourth quarter valued at about $80,000. NBC Securities Inc. raised its position in TG Therapeutics by 34.5% in the fourth quarter. NBC Securities Inc. now owns 9,401 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 2,409 shares in the last quarter. Finally, Trust Co of the South acquired a new position in TG Therapeutics in the fourth quarter worth about $181,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Price Performance

TGTX opened at $17.65 on Monday. TG Therapeutics, Inc. has a one year low of $6.46 and a one year high of $26.95. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.62 and a quick ratio of 2.84. The company’s 50 day simple moving average is $16.03 and its 200-day simple moving average is $15.99. The stock has a market capitalization of $2.73 billion, a P/E ratio of 76.74 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). TG Therapeutics had a net margin of 14.24% and a return on equity of 31.34%. The company had revenue of $63.47 million for the quarter, compared to the consensus estimate of $54.60 million. During the same period last year, the company earned ($0.28) earnings per share. TG Therapeutics’s revenue for the quarter was up 713.5% compared to the same quarter last year. Sell-side analysts anticipate that TG Therapeutics, Inc. will post -0.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on TGTX. The Goldman Sachs Group increased their price target on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Thursday, February 29th. HC Wainwright increased their price target on shares of TG Therapeutics from $45.00 to $49.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. LADENBURG THALM/SH SH increased their price target on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Finally, JPMorgan Chase & Co. reissued an “overweight” rating and issued a $25.00 price target on shares of TG Therapeutics in a research report on Thursday, April 18th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $29.83.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.